Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2115791 | 0.94 | S1PR1 (0.47) | S1PR1S1PR3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2117141 | 0.86 | S1PR1 (0.43) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2115235 | 0.85 | S1PR1 (0.43) | S1PR1S1PR3KCNH2PNMT | |
| SCHEMBL2115539 | 0.84 | S1PR1 (0.41) | S1PR1S1PR3KCNH2CD274PNMT | |
| SCHEMBL2117220 | 0.84 | S1PR1 (0.67) | S1PR1S1PR3KCNH2 | |
| Hydrochloric Acid SCHEMBL2115256 | 0.83 | S1PR1 (0.41) | S1PR1S1PR3KCNH2CD274PNMT | |
| SCHEMBL2117919 | 0.80 | S1PR1 (0.62) | S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL2120186 | 0.79 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL2602067 | 0.77 | S1PR1 (0.66) | S1PR1S1PR3KCNH2 | |
| Hydrochloric Acid SCHEMBL2115459 | 0.77 | S1PR1 (0.65) | S1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | claimed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885KCNH2 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.